BofA analyst Greg Harrison initiated coverage of Keros Therapeutics with a Buy rating and $65 price target. The company offers a “differentiated approach” to develop drugs in hematology and pulmonary indications, the analyst tells investors in a research note. The firm believes both KER-050 and KER-012 have blockbuster potential, even with minority market shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KROS:
- Keros Therapeutics to host conference call on KER-012 Phase 2 trial
- Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
- Keros will not participate in fireside chat at Goldman Sachs conference
- Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference
- Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association